The total return over the past 12 months is -0.93% vs. +16.94% for the S&P 500. So far it's up -20.23% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (0.93%) | +88.15% | (0.24%) | N/A | N/A | N/A |
| Total Return CAGR | (0.93%) | +88.15% | (0.24%) | N/A | N/A | N/A |
| Revenue CAGR | (86.20%) | +46.10% | N/A | N/A | N/A | N/A |
| Net Income CAGR | (496.12%) | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | (473.33%) | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | (395.49%) | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | (388.95%) | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Stoke Therapeutics, Inc. (STOK)
| Year | Start price | End price | STOK Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $31.74 | $25.32 | (20.23%) | +14.51% | (34.74%) |
| 2025 | $11.03 | $31.74 | +187.76% | +17.72% | +170.04% |
| 2024 | $5.26 | $11.03 | +109.70% | +24.89% | +84.81% |
| 2023 | $9.23 | $5.26 | (43.01%) | +26.19% | (69.20%) |
| 2022 | $23.99 | $9.23 | (61.53%) | (18.17%) | (43.36%) |
| 2021 | $61.93 | $23.99 | (61.26%) | +28.74% | (90.00%) |
| 2020 | $28.32 | $61.93 | +118.68% | +18.37% | +100.31% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
